Literature DB >> 12643149

Epidemiology of the insulin resistance syndrome.

James B Meigs1.   

Abstract

The insulin resistance syndrome consists of the co-occurrence of metabolic risk factors for type 2 diabetes and cardiovascular disease, including overall obesity, central obesity, dyslipidemia (characterized by elevated levels of triglycerides and low levels of high-density lipoprotein cholesterol), hyperglycemia, and hypertension. Using criteria proposed by the National Cholesterol Education Program Adult Treatment Panel III, national survey data suggest the insulin resistance syndrome is very common, affecting about 24% of US adults aged greater than 20 years. The syndrome is more common in older people and in Mexican Americans, and will increase in prevalence as populations age and become more obese. Identification of the syndrome warrants aggressive interventions known to prevent type 2 diabetes and cardiovascular disease, including weight reduction, increased physical activity, and control of hypertension and dyslipidemia.

Entities:  

Mesh:

Year:  2003        PMID: 12643149     DOI: 10.1007/s11892-003-0057-2

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  47 in total

1.  Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome.

Authors:  A H Kissebah; G E Sonnenberg; J Myklebust; M Goldstein; K Broman; R G James; J A Marks; G R Krakower; H J Jacob; J Weber; L Martin; J Blangero; A G Comuzzie
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

2.  Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state.

Authors:  S M Haffner; L Mykkänen; A Festa; J P Burke; M P Stern
Journal:  Circulation       Date:  2000-03-07       Impact factor: 29.690

3.  Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study.

Authors:  J B Meigs; R B D'Agostino; P W Wilson; L A Cupples; D M Nathan; D E Singer
Journal:  Diabetes       Date:  1997-10       Impact factor: 9.461

4.  Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.

Authors:  M N Ghazzi; J E Perez; T K Antonucci; J H Driscoll; S M Huang; B W Faja; R W Whitcomb
Journal:  Diabetes       Date:  1997-03       Impact factor: 9.461

5.  TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus.

Authors:  S P Azen; R K Peters; K Berkowitz; S Kjos; A Xiang; T A Buchanan
Journal:  Control Clin Trials       Date:  1998-04

6.  Cardiovascular morbidity and mortality associated with the metabolic syndrome.

Authors:  B Isomaa; P Almgren; T Tuomi; B Forsén; K Lahti; M Nissén; M R Taskinen; L Groop
Journal:  Diabetes Care       Date:  2001-04       Impact factor: 19.112

7.  Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group.

Authors: 
Journal:  Diabetes Care       Date:  1999-07       Impact factor: 19.112

8.  Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study.

Authors:  X R Pan; G W Li; Y H Hu; J X Wang; W Y Yang; Z X An; Z X Hu; J Lin; J Z Xiao; H B Cao; P A Liu; X G Jiang; Y Y Jiang; J P Wang; H Zheng; H Zhang; P H Bennett; B V Howard
Journal:  Diabetes Care       Date:  1997-04       Impact factor: 19.112

9.  Factors of insulin resistance syndrome--related phenotypes are linked to genetic locations on chromosomes 6 and 7 in nondiabetic mexican-americans.

Authors:  Rector Arya; John Blangero; Ken Williams; Laura Almasy; Thomas D Dyer; Robin J Leach; Peter O'Connell; Michael P Stern; Ravindranath Duggirala
Journal:  Diabetes       Date:  2002-03       Impact factor: 9.461

10.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

Authors:  K G Alberti; P Z Zimmet
Journal:  Diabet Med       Date:  1998-07       Impact factor: 4.359

View more
  18 in total

Review 1.  Influence of obesity and metabolic dysfunction on the endothelial control in the coronary circulation.

Authors:  Eric J Belin de Chantemele; David W Stepp
Journal:  J Mol Cell Cardiol       Date:  2011-08-26       Impact factor: 5.000

2.  Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study.

Authors:  Andreas Pfützner; Markolf Hanefeld; Lida A Dekordi; Jürgen Müller; Iris Kleine; Winfried Fuchs; Thomas Forst
Journal:  J Diabetes Sci Technol       Date:  2011-07-01

3.  A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer.

Authors:  Geoffrey C Kabat; Mimi Kim; Rowan T Chlebowski; Janu Khandekar; Marcia G Ko; Anne McTiernan; Marian L Neuhouser; Donna R Parker; James M Shikany; Marcia L Stefanick; Cynthia A Thomson; Thomas E Rohan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-06-30       Impact factor: 4.254

4.  The benefits of restraint: a pivotal role for IL-13 in hepatic glucose homeostasis.

Authors:  Mariana Verdelho Machado; Yiping Yang; Anna Mae Diehl
Journal:  J Clin Invest       Date:  2012-12-21       Impact factor: 14.808

5.  Plasma lipidome is independently associated with variability in metabolic syndrome in Mexican American families.

Authors:  Hemant Kulkarni; Peter J Meikle; Manju Mamtani; Jacquelyn M Weir; Marcio Almeida; Vincent Diego; Juan Manuel Peralta; Christopher K Barlow; Claire Bellis; Thomas D Dyer; Laura Almasy; Michael C Mahaney; Anthony G Comuzzie; Harald H H Göring; Joanne E Curran; John Blangero
Journal:  J Lipid Res       Date:  2014-03-13       Impact factor: 5.922

6.  Metabolic phenotypes of obesity: frequency, correlates and change over time in a cohort of postmenopausal women.

Authors:  G C Kabat; W Y-Y Wu; J W Bea; C Chen; L Qi; M L Stefanick; R T Chlebowski; D S Lane; J Wactawski-Wende; S Wassertheil-Smoller; T E Rohan
Journal:  Int J Obes (Lond)       Date:  2016-10-17       Impact factor: 5.095

7.  A longitudinal study of the metabolic syndrome and risk of colorectal cancer in postmenopausal women.

Authors:  Geoffrey C Kabat; Mimi Y Kim; Ulrike Peters; Marcia Stefanick; Lifang Hou; Jean Wactawski-Wende; Catherine Messina; James M Shikany; Thomas E Rohan
Journal:  Eur J Cancer Prev       Date:  2012-07       Impact factor: 2.497

Review 8.  Should the insulin resistance syndrome be treated in the elderly?

Authors:  Richard W Grant; James B Meigs
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

9.  Advantages of the single delay model for the assessment of insulin sensitivity from the intravenous glucose tolerance test.

Authors:  Simona Panunzi; Andrea De Gaetano; Geltrude Mingrone
Journal:  Theor Biol Med Model       Date:  2010-03-18       Impact factor: 2.432

10.  Impaired sodium excretion and increased blood pressure in mice with targeted deletion of renal epithelial insulin receptor.

Authors:  Swasti Tiwari; Nikhil Sharma; Pritmohinder S Gill; Peter Igarashi; C Ronald Kahn; James B Wade; Carolyn M A Ecelbarger
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.